A real world study on the clinical treatment of hypertension patients with Levamlodipine Besylate Tablets (Shi Hui Da) after marketing

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028731

Enrollment

Unknown

Registered

2020-01-01

Start date

2019-07-24

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Experimental group:Taking Shi-Hui-Da for hypertension

Control group:Taking Amlodipine or Adalat or Plendil for hypertension

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Systolic blood pressure >=140mmHg and/or diastolic blood pressure >=90mmHg, or receiving antihypertensive medication; 3. Taking Levamlodipine Besylate Tablets (Shi Hui Da) or other CCB class drugs (Amlodipine, Adalat and Plendil), with baseline data and medical records; 4. Willing to sign the informed consent and accept the interviewees.

Exclusion criteria

Exclusion criteria: Contraindications of Levamlodipine Besylate Tablets (Shi Hui Da) and other CCB drugs (Amlodipine, Adalat and Plendil)

Design outcomes

Primary

Measure	Time frame
The rate blood pressure target achievement;	—

Secondary

Measure	Time frame
Drug economy ofLevamlodipine Besylate and Amlodipine, Adalat and Plendil;Cardiovascular and cerebrovascular complex endpoint events;	—

Countries

China

Contacts

Public ContactYouhong Jia

Fuwai Hospital, Chinese Academy of Medical Sciences

fwjyh07@163.com+86 13611116637

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026